Autopsy report · NCT00827671

Study of Combination of Cetuximab and Radiotherapy Added to the Standard Treatment for Oesophageal Adenocarcinoma

“Experimental treatment not feasible due to high rate of drop out”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 months before it started.
• Ran for about 7 years before it stopped.
• 12 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

P.O. Witteveen

Sponsor type

University, hospital or other

Conditions

Resectable Esophageal Cancer

Interventions

cetuximab; radiotherapy to oesophageal tumour

Participants

12

Sites

1

Countries

Netherlands

Trials that died the same way

• Giant Cell Arteritis and Anakinra Trial
  “experimental treatment no longer available” (62% match in meaning)
• Phase II Study of TPA Plus Dexamethasone & CMT in Hematologic Malignancies
  “Study was terminated early due to lack of experimental medication (supply issues)” (57% match in meaning)
• Efficacy of the Infusion of Donor Plasma in COVID-19 Infection
  “Lack of efficacy of treatment tested” (55% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.